Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 7
Submit an article Journal homepage
1,780
Views
2
CrossRef citations to date
0
Altmetric
Letters to Editor

Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma

Paul M. Barra Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9733-401XView further author information
ORCID Icon,
Stephen D. Smithb University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USAView further author information
,
Mark J. Roschewskic National Cancer Institute, Bethesda, MD, USAORCID Iconhttps://orcid.org/0000-0003-0278-2635View further author information
ORCID Icon,
Susan M. O’Briend Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA, USAView further author information
,
Jeff P. Sharmane Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, USAView further author information
,
Jason M. Melearf Texas Oncology, Austin, TX, USAView further author information
,
Priti Patelg AstraZeneca, South San Francisco, CA, USAView further author information
,
Roser Calvoh AstraZeneca, Gaithersburg, MD, USAView further author information
,
Helen Yangg AstraZeneca, South San Francisco, CA, USAView further author information
&
Stephen E. Spurgeoni Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR, USAView further author information
 show all
Pages 1728-1732 | Received 20 Sep 2021, Accepted 08 Feb 2022, Published online: 24 Feb 2022

References

  • Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88–92.
  • Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–1947.
  • Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–926.
  • Lenz G, Hawkes E, Verhoef G, et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia. 2020;34(8):2184–2197.
  • Calquence [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2019.
  • Barf T, Covey T, Izumi R, et al. Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther. 2017;363(2):240–252.
  • Lanasa MC, Glenn M, Mato AR, et al. First-in-human study of AMG 319, a highly selective, small molecule inhibitor of PI3Kδ, in adult patients with relapsed or refractory lymphoid malignancies [abstract. Blood. 2013;122(21):678–678. ].
  • Suzuki H, Matsuda S, Terauchi Y, et al. PI3K and btk differentially regulate B cell antigen receptor-mediated signal transduction. Nat Immunol. 2003;4(3):280–286.
  • Mathews Griner LA, Guha R, Shinn P, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A. 2014;111(6):2349–2354.
  • Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenström macroglobulinaemia: update from the VIth international workshop. Br J Haematol. 2013;160(2):171–176.
  • Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer Institute-Working group 1996 guidelines. Blood. 2008;111(12):5446–5456.
  • Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
  • Hsu C, Marshall JL, He AR. Workup and management of immune-mediated hepatobiliary pancreatic toxicities that develop during immune checkpoint inhibitor treatment. Oncologist. 2020;25(2):105–111.
  • Patnaik A, Appleman LJ, Tolcher AW, et al. First-in-human phase I study of copanlisib (Bay 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas. Ann Oncol. 2016;27(10):1928–1940.
  • Ukoniq [package insert]. Edison, NJ: TG Therapeutics; 2021.
  • Flinn IW, O'Brien S, Kahl B, et al. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. Blood. 2018;131(8):877–887.
  • Ramanathan S, Jin F, Sharma S, et al. Clinical pharmacokinetic and pharmacodynamic profile of idelalisib. Clin Pharmacokinet. 2016;55(1):33–45.
  • Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390–3397.
  • Spriano F, Tarantelli C, Gaudio E, et al. Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas. Br J Haematol. 2019;187(5):595–601.
  • Yahiaoui A, Meadows SA, Sorensen RA, et al. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors. PLoS One. 2017;12(2):e0171221.
  • Jain N, Singh S, Laliotis G, et al. Targeting phosphatidylinositol 3 kinase-β and -δ for bruton tyrosine kinase resistance in diffuse large B-cell lymphoma. Blood Adv. 2020;4(18):4382–4392.
  • Barr PM, Saylors GB, Spurgeon SE, et al. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood. 2016;127(20):2411–2415.
  • Davids MS, Kim HT, Nicotra A, et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. Lancet Haematol. 2019;6(1):e38–e47.
  • Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.